電子期刊
台灣家庭醫學雜誌
李喬霖1 戴致一2 柯澐蓁1,3*
(台灣家醫誌2024; 34: 227-233) DOI: 10.53106/168232812024123404005
關鍵詞:缺血性腦中風、抗血小板藥物、淨效益、cilostazol
1臺北市立聯合醫院陽明院區家庭醫學科
2臺北市立聯合醫院陽明院區藥劑科
3輔仁大學醫學系
受理日期:113年9月10日 修改日期:113年11月3日 同意刊登:113年11月14日
*通訊作者:柯澐蓁 通訊地址:臺北市士林區雨聲街105號 E-mail: DXO88@tpech.gov.tw
Selection of Antiplatelet Drugs for Preventing RecurrentStroke in Non-cardiogenic Ischemic Stroke withRecurrent Gastrointestinal Bleeding: A Case Report
Chiao-Lin Li1, Chih-I Tai2 and Yun-Chen Ko1,3*
In Taiwan, the incidence rate of stroke is approximately 300 to 500 per 100,000 people, withischemic stroke accounting for approximately 74% of the cases. Antiplatelet medications, especiallyaspirin and clopidogrel, are commonly used to prevent recurrent ischemic stroke but may increasethe risk of bleeding, even potentially life-threatening severe bleeding, in some patients. Therefore,achieving the maximum net benefit is an important issue. This case report presents a patient whorequired antiplatelet medication for preventing recurrent ischemic stroke but experienced repeatedgastrointestinal bleeding. Unable to tolerate aspirin or clopidogrel, the patient was prescribedcilostazol for the prevention of recurrent ischemic stroke. Follow-up for approximately one yearfound no recurrence of gastrointestinal bleeding or stroke in this case.
(Taiwan J Fam Med 2024; 34: 227-233) DOI: 10.53106/168232812024123404005
Key words: antiplatelet drugs, cilostazol, ischemic stroke, net benefit
1Department of Family Medicine, Taipei City Hospital, Yangming Branch
2Department of Pharmacy, Taipei City Hospital, Yangming Branch
3School of Medicine, Fu Jen Catholic University
Received: September 10, 2024; Revised: November 3, 2024; Accepted: November 14, 2024.
*Corresponding author